References
- Cutler NR, Jhee SS, Majumdar AK, et al. Pharmacokinetics of rizatriptan tablets during and between attacks. Headache 1999;39:264–9
- Sullivan TJ. Cross-reactions among furosemide, hydro-chlorothiazide, and sulfonamides. JAMA 1991;265:120–1
- Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998;55:889–922
- Longmore J, Dowson AJ, Hill RG. Advances in migraine therapy – 5-HT receptor subtype-specific agonist drugs. Curr Opin CPNS Invest Drugs 1999;1: 39–53
- Hargreaves RJ, Longmore J, Beer M, et al. The pharmacology and mechanisms of action of rizatriptan. In HC Diener, ed. Drug Treatment of Migraine and other Headaches. Monographs in Clinical Neuroscience. Basel: Karger, 2000; 17:141–61
- Dahlöf CGH, Rapoport AM, Sheftell FD, Lines CR. Rizatriptan in the treatment of migraine. Clin Ther 1999; 21:1823–36
- Goldberg MR, Sciberras D, De Smet M, et al. Influence of beta adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist. Br J Clin Pharmacol 2001; in press
- Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998;38:184– 90
- Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998;38: 748–55
- Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg vs sumatriptan 25 mg and 50 mg in migraine. Headache 1998;38: 737–47
- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 (Suppl 7):1–96
- Allen C, Jiang K, Malbecq W, Goadsby PJ. Time-to-event analysis, or who gets better sooner? An emerging concept in headache study methodology. Cephalalgia 1999;1:552–6
- International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20:765–86
- Pascual J, Lipton RB, McCarroll KA, Lines CR. Efficacy of rizatriptan and sumatriptan for treating migraine-associated nausea. Headache 2000;40:423 (Abstract)
- Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan vs. other triptans on a composite measure of efficacy at 2 hours: freedom from pain and associated symptoms. Headache 2000;40:401 (Abstract)
- Ferrari MD. Migraine. Lancet 1998;351:1043–51
- Ferrari MD, Lipton RB, McCarroll KA, et al. 24-hour sustained pain free status after rizatriptan and other triptans: a comparison. Headache 2000;40:407–8 (Abstract)
- Dahlöf CGH, Lipton RB, McCarroll KA, et al. Within-patient consistency of response of rizatriptan for treating migraine. Neurology 2000;55:1511–16
- Loder E, Boyle D, Wang L, et al. Comparison of preference for MAXALT-MLT 10 mg or IMITREX 50 mg tablet for the acute treatment of migraine. Poster presented at Headache World 2000, London, UK, September 3–7, 2000
- Lipton RB, Stewart WF. Acute migraine therapy: Do doctors understand what patients want from therapy? Headache 2000;39(Suppl 2):S20–26
- Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000; 22:1035–48
- Hu XH, Raskin N, Cowan R, Berger M. Migraine attack treatment with rizatriptan: timing of medication use and clinical outcomes. Neurology 2000;54\(Suppl 3):A267 (Abstract)
- Gerth WC, Mannix L, McCarroll KA, et al. Patient satisfaction with rizatriptan 10 mg vs. other triptans: head-to-head comparisons. Headache 2000;40:408–9 (Abstract)